Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Jessica A Finlay-Schultz

TitleAsst Professor-Research
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-Pathology

    Collapse Research 
    Collapse research activities and funding
    F32CA177081     (FINLAY-SCHULTZ, JESSICA)Jan 22, 2014 - Jan 21, 2017
    NIH
    Tumor-specific actions of progestins in patient-derived breast cancer models
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. McGinn O, Riley D, Finlay-Schultz J, Paul KV, Kabos P, Sartorius CA. Cytokeratins 5 and 17 Maintain an Aggressive Epithelial State in Basal-Like Breast Cancer. Mol Cancer Res. 2022 09 02; 20(9):1443-1455. PMID: 35639459.
      View in: PubMed
    2. Ward AV, Matthews SB, Fettig LM, Riley D, Finlay-Schultz J, Paul KV, Jackman M, Kabos P, MacLean PS, Sartorius CA. Estrogens and Progestins Cooperatively Shift Breast Cancer Cell Metabolism. Cancers (Basel). 2022 Mar 31; 14(7). PMID: 35406548.
      View in: PubMed
    3. Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, Jindal S, Hui M, Finlay-Schultz J, Ebrahimie E, Birrell SN, Stelloo S, Iggo R, Alexandrou S, Caldon CE, Abdel-Fatah TM, Ellis IO, Zwart W, Palmieri C, Sartorius CA, Swarbrick A, Lim E, Carroll JS, Tilley WD. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat Med. 2021 02; 27(2):310-320. PMID: 33462444.
      View in: PubMed
    4. Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim HM, Tan AC, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. Clin Cancer Res. 2021 01 15; 27(2):585-597. PMID: 33097494.
      View in: PubMed
    5. Finlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, Harrell JC, Kabos P, Sartorius CA. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res. 2020 06 23; 22(1):68. PMID: 32576280.
      View in: PubMed
    6. Brechbuhl HM, Barrett AS, Kopin E, Hagen JC, Han AL, Gillen AE, Finlay-Schultz J, Cittelly DM, Owens P, Horwitz KB, Sartorius CA, Hansen K, Kabos P. Fibroblast subtypes define a metastatic matrisome in breast cancer. JCI Insight. 2020 02 27; 5(4). PMID: 32045383.
      View in: PubMed
    7. McGinn O, Ward AV, Fettig LM, Riley D, Ivie J, Paul KV, Kabos P, Finlay-Schultz J, Sartorius CA. Cytokeratin 5 alters ?-catenin dynamics in breast cancer cells. Oncogene. 2020 03; 39(12):2478-2492. PMID: 31988452.
      View in: PubMed
    8. Riemondy KA, Ransom M, Alderman C, Gillen AE, Fu R, Finlay-Schultz J, Kirkpatrick GD, Di Paola J, Kabos P, Sartorius CA, Hesselberth JR. Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq libraries. Nucleic Acids Res. 2019 02 28; 47(4):e20. PMID: 30496484.
      View in: PubMed
    9. Finlay-Schultz J, Gillen AE, Brechbuhl HM, Ivie JJ, Matthews SB, Jacobsen BM, Bentley DL, Kabos P, Sartorius CA. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III. Cancer Res. 2017 09 15; 77(18):4934-4946. PMID: 28729413.
      View in: PubMed
    10. Fettig LM, McGinn O, Finlay-Schultz J, LaBarbera DV, Nordeen SK, Sartorius CA. Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells. Oncogene. 2017 11 02; 36(44):6074-6084. PMID: 28692043.
      View in: PubMed
    11. Wellberg EA, Johnson S, Finlay-Schultz J, Lewis AS, Terrell KL, Sartorius CA, Abel ED, Muller WJ, Anderson SM. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis. Breast Cancer Res. 2016 12 20; 18(1):131. PMID: 27998284.
      View in: PubMed
    12. Hanna C, Kwok L, Finlay-Schultz J, Sartorius CA, Cittelly DM. Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies. J Vis Exp. 2016 11 30; (117). PMID: 27929464.
      View in: PubMed
    13. Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clin Cancer Res. 2017 Apr 01; 23(7):1710-1721. PMID: 27702820.
      View in: PubMed
    14. Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, Sartorius CA. Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2015 Nov; 25(9):1565-73. PMID: 26495758.
      View in: PubMed
    15. Finlay-Schultz J, Sartorius CA. Steroid hormones, steroid receptors, and breast cancer stem cells. J Mammary Gland Biol Neoplasia. 2015 Jun; 20(1-2):39-50. PMID: 26265122.
      View in: PubMed
    16. Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2015 Jul; 34(28):3676-87. PMID: 25241899.
      View in: PubMed
    17. Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat. 2012 Sep; 135(2):415-32. PMID: 22821401.
      View in: PubMed
    18. Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA, Richer JK. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene. 2013 May 16; 32(20):2555-64. PMID: 22751119.
      View in: PubMed
    19. Canastar A, Logel J, Graw S, Finlay-Schultz J, Osborne C, Palionyte M, Drebing C, Plehaty M, Wilson L, Eyeson R, Leonard S. Promoter methylation and tissue-specific transcription of the a7 nicotinic receptor gene, CHRNA7. J Mol Neurosci. 2012 Jun; 47(2):389-400. PMID: 22052086.
      View in: PubMed
    20. Finlay-Schultz J, Canastar A, Short M, El Gazzar M, Coughlan C, Leonard S. Transcriptional repression of the a7 nicotinic acetylcholine receptor subunit gene (CHRNA7) by activating protein-2a (AP-2a). J Biol Chem. 2011 Dec 09; 286(49):42123-42132. PMID: 21979958.
      View in: PubMed
    Finlay-Schultz's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (131) concept(s)
    _
    Co-Authors Expand Description
    See all (28) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)